Apimeds Pharmaceuticals US, Inc. (APUS) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$6.0M, or -$5.50 per diluted share. Operating activities generated -$8.9M of cash, leaving -$9.0M of free cash flow. At fiscal year end, Apimeds Pharmaceuticals US held $164.2M in total assets against $10.8M in total liabilities, including $1.6M of cash and equivalents.
Open the full interactive Apimeds Pharmaceuticals US financials → Quarterly statements, key ratios, valuation history and price charts.
Apimeds Pharmaceuticals US Key Stats
| Share Price | $4.62 |
|---|---|
| Market Cap | $7.9M |
| 52-Week Range | $1.60 – $38.95 |
| Shares Outstanding | 1.7 million (basic, 2026 Q2) |
Apimeds Pharmaceuticals US Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | — |
| Operating Income | -$1.3M | -$11.9M |
| Pre-Tax Income | -$1.4M | -$6.0M |
| Net Income | -$1.4M | -$6.0M |
| Diluted EPS | -$1.80 | -$5.50 |
Apimeds Pharmaceuticals US Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | — | $0 | $0 |
| Net Income | -$1.8M | -$1.2M | -$35.1M | -$20.2M |
| Diluted EPS | -$1.40 | -$0.11 | -$22.60 | -$11.77 |
Apimeds Pharmaceuticals US Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $3,455 | $1.6M |
| Current Assets | $13,057 | $14.0M |
| Total Assets | $13,057 | $164.2M |
| Current Liabilities | $1.0M | $10.7M |
| Total Liabilities | $1.4M | $10.8M |
| Shareholders' Equity | -$1.4M | $153.3M |
Apimeds Pharmaceuticals US Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$733,526 | -$8.9M |
| Cash From Investing | — | -$10.1M |
| Cash From Financing | $326,500 | $20.6M |
| Free Cash Flow | — | -$9.0M |
Figures from Apimeds Pharmaceuticals US's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Apimeds Pharmaceuticals US financials page for every line item.
Apimeds Pharmaceuticals US Company Profile
| Ticker | APUS |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Matawan, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001894525 |
Frequently Asked Questions
What was Apimeds Pharmaceuticals US's net income in fiscal 2025?
Apimeds Pharmaceuticals US reported net income of -$6.0M for fiscal 2025.
What was Apimeds Pharmaceuticals US's earnings per share (EPS) in fiscal 2025?
Apimeds Pharmaceuticals US's diluted EPS was -$5.50 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Apimeds Pharmaceuticals US generate in fiscal 2025?
Apimeds Pharmaceuticals US generated -$9.0M of free cash flow in fiscal 2025.
What was Apimeds Pharmaceuticals US's revenue last quarter?
In its most recent reported quarter (2026 Q2), Apimeds Pharmaceuticals US reported revenue of $0.
How many shares of Apimeds Pharmaceuticals US are outstanding?
Apimeds Pharmaceuticals US reported a weighted average of 1.7 million basic shares outstanding in 2026 Q2.
What is Apimeds Pharmaceuticals US's market cap?
Based on its latest closing price, Apimeds Pharmaceuticals US (APUS) has a market capitalization of about $7.9M.
When does Apimeds Pharmaceuticals US's fiscal year end?
Apimeds Pharmaceuticals US's fiscal year end, as registered with the SEC, is December 31.
Where is Apimeds Pharmaceuticals US headquartered?
Apimeds Pharmaceuticals US lists its business address in Matawan, New Jersey in its SEC filings.